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Epidemiology of Burkholderia 
cepacia Complex in Patients 
with Cystic Fibrosis, Canada
David P. Speert,* Deborah Henry,* Peter Vandamme,† Mary Corey,‡ 
and Eshwar Mahenthiralingam*
The Burkholderia cepacia complex is an important group of pathogens in patients with cystic fibrosis (CF).
Although evidence for patient-to-patient spread is clear, microbial factors facilitating transmission are
poorly understood. To identify microbial clones with enhanced transmissibility, we evaluated B. cepacia
complex isolates from patients with CF from throughout Canada. A total of 905 isolates from the B. cepacia
complex were recovered from 447 patients in 8 of the 10 provinces; 369 (83%) of these patients had
genomovar III and 43 (9.6%) had B. multivorans (genomovar II). Infection prevalence differed substantially
by region (22% of patients in Ontario vs. 5% in Quebec). Results of typing by random amplified polymor-
phic DNA analysis or pulsed-field gel electrophoresis indicated that strains of B. cepacia complex from
genomovar III are the most potentially transmissible and that the B. cepacia epidemic strain marker is a
robust marker for transmissibility.
urkholderia cepacia complex is an important group of
pathogens in immunocompromised hosts, notably those
with cystic fibrosis (CF) or chronic granulomatous disease
(1,2). Lung infections with B. cepacia complex in certain
patients with CF result in rapidly progressive, invasive, fatal
bacteremic disease (3). Furthermore, the bacteria have a poten-
tial for patient-to-patient spread, both within and outside the
hospital (4-9), raising questions about optimal measures for
infection control.
The disease risk for infection with B. cepacia complex in
patients with CF is substantially higher than with Pseudomo-
nas aeruginosa alone or with bacteria other than B. cepacia or
P. aeruginosa (10). However, there is a dramatic heterogeneity
in outcome among CF patients infected with B. cepacia com-
plex: some patients have a fulminant decline in pulmonary
function, and others harbor B. cepacia complex for extended
periods of time with no obvious adverse effects. The marked
difference in prognosis among infected patients has not been
adequately explained but is thought to result in part from dif-
ferences among infecting strains of B. cepacia complex. 
B. cepacia is a genetically highly diverse class of bacteria,
which is composed of several different species and discrete
groups constituting the B. cepacia complex (11). Each group
differs sufficiently from the others to constitute a species, and
those that are phenotypically distinct have been assigned spe-
cies designation. Those that cannot be differentiated phenotyp-
ically but are genetically distinct are defined as genomovars
(11). As phenotypic differentiation among the genomovars has
improved over the past decade, new species designation has
been assigned as follows: genomovar II = B. multivorans,
genomovar IV = B. stabilis, genomovar V = B. vietnamiensis,
and genomovar VII = B. ambifaria. Genomovars I and III can-
not be differentiated phenotypically, nor can B. multivorans
and genomovar VI; these species must be distinguished by
genetic methods. Bacteria from each of the genomovars have
been recovered from patients with CF, but the predominant
isolates in North America are from genomovar III and B. mul-
tivorans (12). 
Numerous questions about the epidemiology of B. cepacia
complex in CF are unanswered; for example, it is not known if
certain genomovars or strains are more virulent than others.
The relative risk for patient-to-patient spread of strains from
each of the different genomovars is also unknown. Two
genetic elements have been identified in strains having a pro-
pensity for epidemic spread. First, cblA, which encodes the
protein for cable pilus production, is found in a single highly
transmissible lineage from genomovar III that clusters among
patients in the United Kingdom and Canada (13). Second, the
B. cepacia epidemic strain marker (BCESM), which encodes a
protein of unknown function, is found in many different strains
from genomovar III, each of which is clustered in specific CF
treatment centers (14). 
Infection with bacteria from the B. cepacia complex has a
profound effect on the lives of patients with CF. Since B. cepa-
cia complex infection can be spread from one CF patient to
another, provisions have been introduced in hospitals to limit
contact among these patients. Infected patients are prohibited
in some countries from attending social gatherings where other
CF patients may be in attendance. Furthermore, since viru-
lence appears to differ among strains and one strain may
replace another, policies have been introduced in some centers
to limit contact among patients who are infected with any
strain from the B. cepacia complex. Lack of a clear under-
standing about the epidemiology of B. cepacia complex and
the relative risk of infection with each of the different genomo-
vars has spawned anxiety and confusion among CF patients,
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their caregivers, and families. Infection control policies have
been developed in an effort to balance the rights of CF patients
with careful consideration of their physical and mental health.
With burgeoning knowledge about the taxonomy, epidemi-
ology, and virulence of the B. cepacia complex, many ques-
tions about appropriate infection control precautions have
been raised. Consensus has been difficult to attain because of
incomplete and conflicting data from various regions through-
out the world. We undertook this study to provide a database
from which infection control questions could begin to be
answered.
In 1994 a B. cepacia complex research and referral reposi-
tory for Canadian CF clinics was established in Vancouver.
Since that time, B. cepacia complex isolates from an estimated
75% of infected Canadian CF patients have been evaluated for
genomovar and species identity, random amplified polymor-
phic DNA (RAPD) strain type, and putative markers of trans-
missibility. These data have permitted inferences about the
potential transmissibility of different strains and facilitated the
development of rational infection control guidelines. We
report data and conclusions from our observations to date.
Materials and Methods
Patients and Clinics
Canadian CF clinics are linked through the Canadian Cys-
tic Fibrosis Foundation, which collates annual summary data
in its patient data registry. Approximately 3,200 patients with
CF receive care at 36 clinics in the 10 provinces. Each clinic
provides care for 20 to 300 patients (median age 17 years).
The number of patients with CF in Canada has increased by
approximately 90 each year since 1994, although the median
survival age has plateaued at approximately 30 years.
In 1994, the Canadian B. cepacia Complex Research and
Referral Repository was established at the British Columbia
Research Institute for Children’s and Women’s Health in Van-
couver. Each clinic director was notified about the new labora-
tory and encouraged to send archived and new isolates of B.
cepacia complex to the Vancouver laboratory for strain typing
and confirmation of species identity (7). At least one isolate
from each infected patient was solicited, as well as subsequent
isolates that were considered phenotypically different. 
Species and Genomovar Determination
A polyphasic scheme (15) was used to determine the spe-
cies or genomovar classification of each isolate. 
Phenotypic Identification of B. cepacia Complex 
and Other Organisms
Isolates were identified as described (15,16): purity, mor-
phology, and hemolysis were observed, and oxidase activity
(Pathotec cytochrome oxidase, Remel, Lenexa, KA) was
tested after growth on Columbia agar with 5% sheep blood
(PML Microbiologicals, Richmond, British Columbia, Can-
ada). Bacteria were incubated for up to 7 days at 35°C in the
following sugars: glucose, maltose, lactose, xylose, sucrose,
and adonitol. Moeller lysine, ornithine, and negative control
were also heavily inoculated and incubated at 35°C for 48
hours. The API 20 NE strip (Biomerieux Vitek Inc., Hazel-
wood, MO) was set up according to manufacturer’s instruc-
tions, except that the strip was incubated at 35°C and observed
at 24 and 48 hours. Growth on MacConkey agar without crys-
tal violet (Difco Laboratories, Detroit, MI) and on B cepacia
selective agar (16) at 35°C was observed at 24 and 48 hours.
Pigment production and growth on tryptic soy agar at 35°C
and 42°C were observed at 24 and 48 hours.
Molecular Methods
Genomovar-Specific PCR for the recA Gene
Polymerase chain reaction (PCR) with selected recA prim-
ers was performed essentially as described (15,17). Tests were
done with the six recA subgroup genomovar-specific primers
(15,17) and a seventh primer pair for genomovar VII as
described (15,18). After amplification, 8 µL of each reaction
mixture was subjected to electrophoresis in 1.5% agarose gel.
PCR products were photographed after ethidium bromide
staining. B. cepacia complex strains that did not react with the
specific primers described above were subjected to nucleotide
sequence analysis of the recA gene (17). Placement in the
complex was then done phylogenetically by analysis of 500 bp
of the N-terminal encoding sequence according to the algo-
rithm described (17).
Speciation with the 16S rRNA Gene
Restriction fragment length polymorphism (RFLP) analy-
sis of the 16S rRNA gene PCR product with the enzyme Dde1
was performed as described (15,17).
Genotypic Identification of B. gladioli
A PCR reaction with primer pair LP1/LP4, directed toward
a species-specific region of the 23S rRNA gene, was used (19). 
Strain Typing of B. cepacia Complex Isolates
Each isolate was evaluated for RAPD strain type by RAPD
analysis (20). If typing results were ambiguous, pulsed-field
gel electrophoresis (PFGE) analysis was performed (21).
Groups of isolates that were unambiguously identical by
RAPD with or without PFGE were each assigned numerical
types. Unique isolates were designated X until another identi-
cal isolate was identified.
Evaluation for Markers of Transmissibility
Southern dot blot analysis was performed (14) to deter-
mine if each isolate encoded either of the genetic markers of
transmissibility (cblA or BCESM).Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002 183
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Results
Isolates Received from Canadian CF Clinics
A total of 922 isolates considered to be B. cepacia com-
plex (or possible B. cepacia complex) by the referring labora-
tory were received through July 2000 (Table 1). These isolates
were recovered from 459 different patients. Most specimens
were received after a request for strains was made in 1994
through the Canadian Cystic Fibrosis Foundation; however, 95
isolates were archived specimens obtained from 1981 to 1991.
Seventeen isolates (from 17 patients) were organisms that had
been misidentified as B. cepacia complex. Fourteen of these
17 isolates had been received before 1997, when information
about the importance of correct identification began to be dis-
seminated by the International B. cepacia Working Group
(http://allserv.rug.ac.be/~tcoenye/). The 17 isolates included 5
of Stenotrophomonas maltophilia; 4 of Pseudomonas species;
3 of Alcaligenes xylosoxidans; and 1 each of Enterobacter
agglomerans, Candida species, mixed gram-positive bacteria,
and 2 undescribed new species. Eighteen isolates belonged to
species that are phenotypically similar to B. cepacia complex
(Table 2). Pandoraea species and B. fungorum have only
recently been described (22,23).
Geographic Distribution of CF Patients Infected 
with B. cepacia Complex
Since this study was conducted by passive ascertainment
of bacterial cultures, the representation from regions of Can-
ada differed considerably. Isolates confirmed as members of
the B. cepacia complex were received from 8 of 10 provinces
(Table 1). Only Saskatchewan, Prince Edward Island, and the
territories (Yukon, Nunavut, and Northwest) did not submit
specimens. 
The consistently monitored data in the Patient Data Regis-
try of the Canadian Cystic Fibrosis Foundation provide good
estimates of regional patterns of B. cepacia complex preva-
lence and repository representation. To provide more stable
estimates and preserve confidentiality in provinces with a
small number of centers, the cumulative prevalence of infec-
tion from 1992 to 1997 is reported for four regions of Canada
(Table 3). The prevalence of B. cepacia complex was highest
in Ontario and in the eastern provinces. Although Quebec and
Ontario are contiguous and have similar populations, the prev-
alence of infection with B. cepacia complex was substantially
higher in Ontario. The provinces west of Ontario had a com-
bined prevalence intermediate between those of Ontario and
the eastern provinces, but this region covers a very large geo-
graphic area, which may include heterogeneous provincial
prevalence rates. 
Although the relative prevalence of different genomovars
varied from province to province, genomovar III was found in
every province in which patients were infected with B. cepacia
complex (Table 1). The only province from which B. multi-
vorans was frequently recovered was British Columbia. Each
isolate of B. multivorans was unique except for those recov-
ered from sibling pairs (24). 
Prevalence of Genomovars and Species of Isolates from
the B. cepacia Complex
All initial isolates and those that appeared phenotypically
different from previously received isolates from individual
patients were evaluated for genomovar and species identity by
a polyphasic scheme involving both biochemical analyses and
molecular methods (recA PCR and 16s rRNA RFLP) (Table 2).
Most isolates (80%) were from genomovar III and included all
strains that clustered in individual centers and appeared to be
transmitted from patient to patient. Approximately 9% of
infected patients were infected with B. multivorans (genomo-
var II), but there was little evidence among these isolates
of genotypic clustering as determined by RAPD and PFGE.
Table 1. Burkholderia cepacia complex isolates and phenotypically similar organisms recovered from patients with cystic fibrosis in Canada
Province
No. of patients from whom 
isolates were submitted
Total no. of isolates 
submitted
No. of genomovar/species submitted from different patients
B. multivorans (genomovar II) III Other
British Columbia 95 394 33 52 20
Alberta 45 55 2 32 13
Manitoba 7 7 3 3 1
Saskatchewan 0 0 0 0 0
Ontario 243 292 2 233 8
Quebec 23 48 3 15 5
Prince Edward Island 0 0 0 0 0
New Brunswick 4 4 0 3 1
Nova Scotia 17 89 0 18 2
Newfoundland 13 16 0 13 0
Territories 0 0 0 0 0
Total (including territories) 447 905 43 369 50RESEARCH
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Isolates from the other genomovars and species (genomovar I,
B. stabilis, B. vietnamiensis, and B. cepacia complex bacteria
of indeterminate genomovar status) were recovered, but at
very low frequency (Table 2). Several patients were infected
with more than one strain or genomovar from the B. cepacia
complex, but in all but one case, one strain replaced another
that had been identified previously. Replacement of genomo-
var II (B. multivorans) by genomovar III occurred in six
patients (24).
Eight patients were infected with B. cepacia complex bac-
teria that did not belong to any of the currently defined genom-
ovars (Table 2). The full-length recA gene was amplified from
these isolates by using primers BCR1 and BCR2 (17). These
strains produced novel recA RFLP products, and none reacted
with the PCR primers developed to identify the current
genomovars (17,18). Their biochemical profile was consistent
with that of the B. cepacia complex (data not shown). Analysis
of the 16S rRNA gene by RFLP demonstrated that these
strains were not B. multivorans, B. vietnamiensis, or genomo-
var VI, since they had the single RFLP profile shared by all the
remaining current genomovars/species (B. stabilis, I, III, and
VII; pattern 2 [17]). The nucleotide sequence of the recA gene
from five isolates representative of these novel strains was
examined phylogenetically (Figure). These strains form two
unique, distinct clusters with the current B. cepacia complex
(Figure), suggesting that they are members of the current com-
plex but may be novel taxonomic groups or subgroups of the
existing genomovars not detected by the current molecular
tests. 
Geographic Distribution of B. cepacia Complex 
from Different Epidemic RAPD Strain Types
We have identified four genetic lineages of B. cepacia
complex genomovar III that cluster by geographic region in
Canada (Table 4). Each of these types was defined by RAPD
and confirmed by PFGE. All the isolates from types 01, 04,
and 06 harbored the BCESM, but only those from RAPD type
02 encoded both BCESM and cblA. 
RAPD type 02 was the predominant genomovar III lineage
in Canada. This is the same clone that is reported to have
spread intercontinentally between Canada and the United
Kingdom and is also known as ET12 (5). The cblA gene codes
for production of a cable pilus thought to enhance adhesion to
epithelial cells. 
Discussion
This analysis of isolates from the B. cepacia complex from
a broad geographic distribution may facilitate insights into the
epidemiology and virulence of this evolving class of bacteria
in patients with CF. Most Canadian CF patients are cared for at
centralized clinics in each province, and the data are relayed to
a central registry at the national office of the Canadian CF
Foundation. Regular audits by the Foundation enhance the
quality of care at the individual CF clinics; as a result, micro-
biologic investigation of CF patient samples is optimized. The
rate of misidentification of B. cepacia complex organisms in
Canada has been very low since standard methods for culture
and identification were publicized in 1997. Our recent experi-
ence contrasts with other reports of misidentification in Can-
ada and the United States (25,26). An estimated 75% of
prevalent B. cepacia infection was reported to the Canadian B.
cepacia Complex Research and Referral Repository, and
regional differences were similar to those recorded in the
patient data registry. Therefore, the data reported here proba-
Table 2. Genomovar or species of Burkholderia cepacia complex or 
phenotypically similar isolates from cystic fibrosis patients in Canada
Species or genomovar
No. of patients infected 
with species or genomovara
Percentage of 
patients (%)












plex (not genomovar I-VII)
81 . 8
Burkholderia fungorum 10 . 2
Burkholderia gladioli 51 . 1
Ralstonia pickettii 51 . 1
Pandoraea spp. 5 1.1
Total 461
aSome patients were counted twice if two or more different strains were recovered.
Table 3. Regional prevalence of cystic fibrosis (CF) patients infected with Burkholderia cepacia complex and representation of their isolates in 
Canadian B. cepacia Research and Referral Repository, 1992–1997
Region of Canada
1996 census, population, 
thousands
No. of CF patients, 
1992-1997
No. (%) of CF patients infected 
with B. cepacia complex
No. (%) of CF patients with sam-
ples of B. cepacia complex in 
repository
West 8,816 975 117 (12) 91 (78)a
Ontario 11,101 1293 285 (22) 241 (85)
Quebec 7,274 1088 55 (5) 16 (29)
East 2,381 405 103 (25) 27 (26)
aArchived samples from the main study center have been excluded here to provide comparative regional estimates.Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002 185
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bly reflect true national trends in prevalence and strain distri-
bution of B. cepacia complex organisms in CF patients in
Canada.
Remarkable differences in prevalence and RAPD strain
type clustering were noted among Canadian provinces. This
was most striking in Ontario and Quebec, Canada’s two most
populous provinces. These provinces are contiguous, but the
prevalence of B. cepacia complex infection was about 10-fold
higher in Ontario than in Quebec. Patients in these two prov-
inces probably had very little contact with each other because
of the geographically wide separation between clinics in the
major population centers (Toronto and Montreal). Further-
more, the difference in primary language between the two
provinces may have discouraged social mixing when opportu-
nities arose. The predominant RAPD strain type recovered
from patients in Ontario (RAPD type 02) was rarely cultured
from patients in Quebec. This strain is prevalent throughout
the United Kingdom and appears to have spread to Britain as
well as to other parts of Canada as a result of common expo-
sures in summer camps in Ontario (9).
Clustering of RAPD strain types by province suggests
patient-to-patient spread. Most isolates of RAPD type 02 in
British Columbia and in the Maritime provinces (Nova Scotia
and Newfoundland) can be traced to care received in Toronto,
where that is the predominant type (E. Tullis, pers. comm.).
Since cohorting of patients was instituted in Canadian clinics
in 1994, the spread of RAPD type 02 has slowed (24). Most
new acquisitions of B. cepacia complex organisms in British
Columbia since 1994 have been B. multivorans (24). Each new
isolate has had a unique genetic fingerprint, suggesting that
acquisition has not been from other patients, but from the envi-
ronment. Recent reports from France and Italy describe the
rhizosphere as an important environmental reservoir for B.
cepacia complex isolates (27,28). We are searching for poten-
tial environmental reservoirs in Canada. 
Clusters of common RAPD strain types in CF clinics have
been from genomovar III. The four common RAPD strain
types (01, 02, 04, and 06) all encode BCESM, but only type 02
encodes cblA. Although the latter appears to enhance adhesion
of the bacteria to epithelial cells, the role of BCESM in trans-
missibility has not been determined. 
Figure. Phylogenetic analysis of the recA gene from the Burkholderia
cepacia complex. The phylogenetic diversity of the B. cepacia complex
observed after nucleotide sequence analysis of the recA gene is
shown. Isolates recovered from Canadian CF patients that are repre-
sentative of strains of currently indeterminate genomovar status (Table
2) appear in bold and lack species identification; all fall within the cur-
rent B. cepacia complex. The tree was drawn as described (16). The
recA sequence from Bordetella pertussis was used as a root, and the
genetic distance is indicated by the bar.
Table 4. Number of cystic fibrosis patients infected with Burkholderia cepacia complex genomovar III RAPD strain type, by Canadian province
Province RAPD strain type
01 02 04 06 Other (BCESM+)a
British Columbia 9 11 16 7 10 (5)
Alberta 2 14 16 0 0
Manitoba 0 1 1 0 1 (0)
Saskatchewan 0 0 0 0 0
Ontario 1 223 2 0 7 (5)
Quebec 5 7 1 0 2 (2)
Prince Edward Island 0 0 0 0 0
N e w  B r u n s w i c k 0020 1  ( 0 )
Nova Scotia 0 2 12 0 4 (0)
Newfoundland 0 13 0 0 0
Total 17 271 50 7 25  (12)
aNumber of patients whose isolates had Burkholderia cepacia epidemic strain marker (BCESM ) in the category “other genomovar III RAPD strain types.”  Strain types 01, 02, 04, 
and 06 all encoded BCESM. RAPD = random amplified polymorphic DNA.RESEARCH
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Evidence of patient-to-patient spread of genomovar III B.
cepacia complex strains has been documented in studies from
different geographic regions (9,24). Our results support the
likelihood that spread of these strains occurs throughout Can-
ada. Most patients infected with genomovar III RAPD type 02
may have acquired the strain directly or indirectly from
patients from Ontario. The factors that enhance such patient-
to-patient spread have not been clearly determined, but segre-
gation appears to have been successful in limiting transmis-
sion. 
B. multivorans (genomovar II), in contrast to genomovar
III, does not appear to have spread from patient to patient in
Canada. Each of the isolates was typed by RAPD, and each
had a unique genetic fingerprint. The only exceptions were
isolates from a sibling pair who transiently shared the same
strain. This observation contrasts with those from other parts
of the world, where B. multivorans has been observed to clus-
ter in CF clinics, suggesting patient-to-patient spread
(12,29,30). The differences between our observations and
those of others may be explained on the basis of difference in
infecting strain types; the Canadian B. multivorans isolates
may lack the putative factors necessary for patient-to-patient
spread. Alternatively, infection control practices in Canada
may differ from those elsewhere. The differences between the
epidemiology of B. multivorans in Canada and the United
Kingdom are analogous to that of Pseudomonas aeruginosa in
CF. No evidence of patient-to-patient spread of P. aeruginosa
in Canada has been documented (despite intensive investiga-
tion), but well-documented outbreaks of epidemic spread
among patients in Liverpool and Manchester, United Kingdom
(31,32), and Melbourne, Australia (33), have been reported. 
The evidence of patient-to-patient spread of bacteria from
the  B. cepacia complex among patients with CF and the
adverse prognosis of those who are infected (10,34) demands
stringent efforts to prevent new acquisition. Strategies have
been introduced in Canada, the United States, the United
Kingdom, and elsewhere to limit spread both within and out-
side hospitals. These strategies appear to have limited the epi-
demic spread of certain clones of B. cepacia complex, but the
prevalence of infection has remained largely unchanged.
Infection control precautions are based on lessons learned
from the control of spread of other respiratory tract pathogens;
they may or may not be relevant for CF, with its unique host-
pathogen relationship. Furthermore, B. cepacia complex is an
opportunistic pathogen and is commonly found in the natural
environment in such places as soil and plant roots (27,28,35-
37). The mode of acquisition of B. cepacia complex in CF
patients appears to be both from other patients and from the
environment. Until more is known about risk factors for acqui-
sition, rational infection control strategies will be difficult to
design. We are attempting to identify the factors that may be
correlated with acquisition of this problematic pathogen in
Canadian patients with CF. 
Acknowledgments
We thank the many CF clinic directors and medical microbiolo-
gists who provided the bacterial isolates, without which this study
would not have been possible. The excellent technical assistance of
Gary Probe, Jocelyn Bischoff, Maureen Campbell, and Julie Fadden
is gratefully acknowledged.
This work was supported by grants from the Canadian Cystic
Fibrosis Foundation (DPS) and the United Kingdom Cystic Fibrosis
Trust (EM; project grant PJ472).
Dr. Speert is Professor and Head of the Division of Infectious and
Immunological Diseases and Assistant Head (Research) of the
Department of Pediatrics, University of British Columbia. His
research is directed at gaining a clearer understanding of the patho-
genesis and epidemiology of bacterial lung infections in patients with
cystic fibrosis.
References
  1. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid
Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev
1996;60:539-74.
    2. Speert DP, Bond M, Woodman RC, Curnutte JT. Infection with
Pseudomonas cepacia in chronic granulomatous disease: role of nonoxida-
tive killing by neutrophils in host defense. J Infect Dis 1994;170:1524-31.
    3. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, et al.
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J
Pediatr 1984;104:206-10.
  4. Govan JR, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, et
al. Evidence for transmission of Pseudomonas cepacia by social contact
in cystic fibrosis. Lancet 1993;342:15-9.
  5. Johnson WM. Intercontinental spread of a highly transmissible clone of
Pseudomonas cepacia proved by multilocus enzyme electrophoresis and
ribotyping. Can J Infect Dis 1994;5:86-8.
  6. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person
transmission of Pseudomonas cepacia between patients with cystic fibro-
sis. Lancet 1990;336:1094-6.
  7. Medical/Scientific  Advisory  Committee—Canadian Cystic Fibrosis
Foundation. Epidemiology of Pseudomonas cepacia in cystic fibrosis.
Can J Infect Dis 1993;4:163-5.
  8. Pegues CF, Pegues DA, Ford DS, Hibberd PL, Carson LA, Raine CM, et
al. Burkholderia cepacia respiratory tract acquisition: epidemiology and
molecular characterization of a large nosocomial outbreak. Epidemiol
Infect 1996;116:309-17.
  9. Pegues DA, Carson LA, Tablan OC, FitzSimmons SC, Roman SB, Miller
JM, et al. Acquisition of Pseudomonas cepacia at summer camps for
patients with cystic fibrosis. J Pediatr 1994;124:694-702.
10. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in
Canada, 1970-1989. Am J Epidemiol 1996;143:1007-17.
11. Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, Coopman R,
et al. Occurrence of multiple genomovars of Burkholderia cepacia in cys-
tic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int
J Syst Bacteriol 1997;47:1188-200.
12. LiPuma JJ. Burkholderia cepacia: management issues and new insights.
Clin Chest Med 1998;19:473-86.
13. Sun L, Jiang R, Steinbach S, Holmes A, Campanelli C, Forstner J, et al.
The emergence of a highly transmissible lineage of cbl+ Pseudomonas
(Burkholderia) cepacia causing CF centre epidemics in North America
and Britain. Nat Med 1995;1:661-6.
14. Mahenthiralingam E, Simpson DA, Speert DP. Identification and charac-
terization of a novel DNA marker associated with epidemic Burkholderia
cepacia strains recovered from patients with cystic fibrosis. J Clin Micro-
biol 1997;35:808-16.Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002 187
RESEARCH
15. Henry DA, Mahenthiralingam E, Vandamme P, Coenye T, Speert DP.
Phenotypic methods for determining genomovar status of the Burkholde-
ria cepacia complex. J Clin Microbiol 2001;39:1073-8.
16. Henry DA, Campbell ME, LiPuma JJ, Speert DP. Identification of
Burkholderia cepacia isolates from patients with cystic fibrosis and use
of a simple new selective medium. J Clin Microbiol 1997;35:614-9.
17. Mahenthiralingam E, Bischof J, Byrne SK, Radomski C, Davies JE, Av-
Gay, et al. DNA-based diagnostic approaches for the identification of
Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholde-
ria multivorans, Burkholderia stabilis, Burkholderia cepacia genomovars
I and III. J Clin Microbiol 2000;38:3165-73.
18. Coenye T, Mahenthiralingam E, Henry D, LiPuma JJ, Laevens S, Gillis
M, et al. Burkholderia ambifaria sp. nov., a novel member of the
Burkholderia cepacia complex including biocontrol and cystic fibrosis-
related isolates. Int J Syst Evol Microbiol 2001;51:1481-90.
19. Whitby PW, Pope LC, Carter KB, LiPuma JJ, Stull TL. Species-specific
PCR as a tool for the identification of Burkholderia gladioli. J Clin
Microbiol 2000;38:282-5.
20. Mahenthiralingam E, Campbell ME, Henry DA, Speert DP. Epidemiol-
ogy of Burkholderia cepacia infection in patients with cystic fibrosis:
analysis by random amplified polymorphic DNA (RAPD) fingerprinting.
J Clin Microbiol 1996;34:2914-20.
21. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Ran-
dom amplified polymorphic DNA typing of Pseudomonas aeruginosa
isolates recovered from patients with cystic fibrosis. J Clin Microbiol
1996;34:1129-35.
22. Coenye T, Falsen E, Hoste B, Ohlen M, Goris J, Govan JRW, et al.
Description of Pandoraea gen. nov. with Pandoraea pulmonicola sp.
nov., Pandoraea apista sp. nov., Pandoraea pnomenusa sp. nov., Pando-
raea sputorum sp. nov. and Pandoraea norimbergensis comb. nov. Int J
Syst Evol Microbiol 2000;50:887-99.
23. Coenye T, Laevens S, Willems A, Ohlen M, Hannant W, Govan JRW, et
al. Burkholderia fungorum sp. nov. and Burkholderia caledonica sp. nov.,
two new species isolated from the environment, animals and human clini-
cal samples. Int J Syst Evol Microbiol 2001;51:1099-107.
24. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle
AM, Wong LTK, et al. Infection with Burkholderia cepacia complex
genomovars in patients with cystic fibrosis: virulent transmissible strains
of genomovar III can replace B. multivorans. Clin Infect Dis
2001;33:1469-75. 
25. Burdge DR, Noble MA, Campbell ME, Krell VL, Speert DP. Xanthomo-
nas maltophilia misidentified as Pseudomonas cepacia in cultures of spu-
tum from patients with cystic fibrosis: a diagnostic pitfall with major
clinical implications. Clin Infect Dis 1995;20:445-8.
26. McMenamin JD, Zaccon TM, Coenye T, Vandamme P, LiPuma JJ.
Misidentification of Burkholderia cepacia in U.S. cystic fibrosis treat-
ment centers: an analysis of 1051 recent sputum isolates. Chest
2000;117:1661-5.
27. Balandreau J, Viallard V, Cournoyer B, Coenye T, Laevens S, Vandamme
P.  Burkholderia cepacia genomovar III is a common plant-associated
bacterium. Appl Environ Microbiol 2001;67:982-5.
28. Fiore A, Laevens S, Bevivino A, Dalmastri C, Tabacchioni S, Vandamme
P, et al.  Burkholderia cepacia complex: distribution of genomovars
among isolates from the maize rhizosphere in Italy. Environ Microbiol
2001;3:137-43.
29. Whiteford ML, Wilkinson JD, McColl JH, Conlon FM, Michie JR, Evans
TJ, et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation
in children with cystic fibrosis following a hospital outbreak. Thorax
1995;50:1194-8.
30. Segonds C, Heulin T, Marty N, Chabanon G. Differentiation of Burkhold-
eria species by PCR-restriction fragment length polymorphism analysis
of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin
Microbiol 1999;37:2201-8.
31. Cheng K, Smyth RL, Govan JRW, Doherty C, Winstanley C, Denning N,
et al. Spread of B-lactam-resistant Pseudomonas aeruginosa in a cystic
fibrosis clinic. Lancet 1996;348:639-42.
32. Jones AM, Govan JRW, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge
TN, Webb AK. Spread of multiresistant strain of Pseudomonas aerugi-
nosa in an adult cystic fibrosis clinic. Lancet 2001;358:557-8.
33. Armstrong DS, Nixon G, Carlin J, Carzino R, Grimwood K. Long-term
outbreak of a transmissible virulent strain of Pseudomonas aeruginosa in
a pediatric cystic fibrosis clinic. Pediatr Pulmonol 2000;Suppl 20:393A.
34. Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR. Pseudomonas
cepacia in lung transplant recipients with cystic fibrosis. Chest
1993;103:466-71.
35. Butler SL, Doherty CJ, Hughes JE, Nelson JW, Govan JRW. Burkholde-
ria cepacia and cystic fibrosis: do natural environments present a poten-
tial hazard? J Clin Microbiol 1995;33:1001-4.
36. Mortensen JE, Fisher MC, LiPuma JJ. Recovery of Pseudomonas cepacia
and other Pseudomonas species from the environment. Infect Control
Hosp Epidemiol 1995;16:30-2.
37. Govan JRW, Hughes JE, Vandamme P. Burkholderia cepacia: medical,
taxonomic and ecological issues. J Med Microbiol 1996;45:1-15.
Address for correspondence: David P. Speert, Room 377, Research Centre,
950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada; fax: 604-875-2226;
e-mail: speert@interchange.ubc.ca